Please assess the completion status of the following clinical trial:

Trial Title: Impact of Antiretroviral Therapy on Metabolic, Skeletal, and Cardiovascular Parameters

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Enrollment in A5257 and intent to enroll in A5001 (ALLRT)~* Signed informed consent~* For A5257 inclusion criteria, please see ClinicalTrials.gov identifier NCT00811954~Exclusion Criteria:~* Diabetes mellitus, (fasting plasma glucose ≥ 126 mg/dL on two occasions or on hypoglycemic medications).~* Known cardiovascular disease (history of myocardial infarction \[MI\], coronary artery bypass graft surgery, percutaneous coronary intervention, stroke, transient ischemic attack, or peripheral arterial disease with ankle-brachial index of less than 0.9 or claudication)~* Uncontrolled hypothyroidism or hyperthyroidism which in the opinion of the site investigator would affect substudy participation~* Current use of statins, fish oil (greater than 2 grams per day), fibric acid derivatives, or niacin (more than 1000 mg per day) (NOTE: Current use of fish oil and niacin is defined as receiving treatment in the 8 weeks prior to study entry)~* Intention to start pharmacological or surgical intervention for weight loss~* Use of any ART in the 30 days before study entry~* For A5257 exclusion criteria, please see ClinicalTrials.gov identifier NCT00811954

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort A (Type: None): ATV/RTV + FTC/TDF~Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF), ritonavir (RTV), and atazanavir (ATV) to be taken orally, once daily.
- Cohort B (Type: None): RAL + FTC/TDF~FTC/TDF orally, once daily, and raltegravir (RAL) orally, twice daily.
- Cohort C (Type: None): DRV/RTV + FTC/TDF~FTC/TDF, darunavir (DRV), and RTV, orally, once daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).